What is ALX Oncology Holdings 6-1 Month Momentum %?
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-24), ALX Oncology Holdings's 6-1 Month Momentum % is 65.35%.
The industry rank for ALX Oncology Holdings's 6-1 Month Momentum % or its related term are showing as below:
ALXO's 6-1 Month Momentum % is ranked better than 83.16% of 1520
companies
in the Biotechnology industry
Industry Median: 2.99
vs ALXO: 65.35
Competitive Comparison of ALX Oncology Holdings's 6-1 Month Momentum %
For the Biotechnology subindustry, ALX Oncology Holdings's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings's 6-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
ALX Oncology Holdings 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of ALX Oncology Holdings's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
ALX Oncology Holdings (ALX Oncology Holdings) Business Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXO has been successfully added to your